Analytical Data
-
Gene name
CDK11A
- Application
-
Alternative Names
CDC2L3, CDC2L2; PITSLRE; Cell division cycle 2-like protein kinase 2; PITSLRE serine/threonine-protein kinase CDC2L2; Galactosyltransferase-associated protein kinase p58/GTA
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UQ88
-
Expression Region
Glu422~Ile646
-
Molecular Weight
29kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK11A, also known as cyclin-dependent kinase 11A, is a crucial member of the CDK family that plays significant roles in cell cycle regulation, transcription, and RNA processing. It has been implicated in various cellular processes, including the regulation of gene expression and the coordination of cell division. Research into CDK11A has gained momentum due to its potential involvement in cancer biology, as abnormal expression or activity of CDK11A can lead to uncontrolled cell proliferation. Furthermore, CDK11A is also linked to neurodegenerative diseases and other pathological conditions, making it a target of interest for therapeutic intervention. Understanding the structure and function of CDK11A, particularly through the development of recombinant proteins, allows researchers to investigate its biochemical properties and interactions within cellular pathways. This enables the identification of novel inhibitors or modulators that could be leveraged for drug development. Recent studies have employed various expression systems to produce recombinant CDK11A, facilitating the exploration of its enzymatic activity and regulation by cyclins and other co-factors. Overall, the study of CDK11A recombinant proteins is pivotal for unraveling the complex molecular mechanisms underlying its role in health and disease and holds promise for advancing targeted therapies in oncology and other areas of medicine.
